Goodwin’s Technology and Life Sciences team advised UroMems, a global company developing innovative, implantable mechatronics technology to treat stress urinary incontinence (SUI), on their €44 million Series C financing round.
The financing round was led by Crédit Mutuel Innovation and joined by the European Innovation Council as well as the existing investors Wellington Partners, Bpifrance, Supernova Invest, Hil-Invent, b-to-v Partners and Financière Arbevel.
The capital will fund Pivotal Clinical Trials of the UroActive™ System, the First Smart Automated Implant to Treat Stress Urinary Incontinence.
The Goodwin team was led by Thomas Dupont-Sentilles and included Julie Messerig on corporate aspects. The team has been advising UroMems since 2016.